At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
armodafinil +1 moredrug
Likely dose
armodafinil 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
In Brief
A Phase 3 clinical trial evaluating armodafinil and Placebo for Fatigue and Multiple Myeloma. Completed, enrolled 50 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatigue, Multiple Myeloma
CountriesUnited States
CollaboratorsCephalon
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJul 2010
Primary CompletionJun 2013
Study CompletionMay 2014
TodayJul 2026
First PostedJul 12, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.0 years ago
Interventions
armodafinildrug
Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
Placebodrug
Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.